Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant SARS-CoV-2 S-Trimer Booster in Healthy Adults
NCT05716347Phase 1Terminated
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SCB-2019 in coronavirus disease 2019 (COVID-19), sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events within 30 minutes, Incidence of Treatment-Emergent Adverse Events within 7 days and 2 more. Started Jul 2022; status: terminated.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05716347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716347.